EMA/388229/2023

European Medicines Agency decision

P/0383/2023

of 7 September 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP07-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0383/2023

of 7 September 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP07-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by AbbVie Ltd on 12 September 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 July 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for upadacitinib (Rinvoq), prolonged-release tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for upadacitinib (Rinvoq), prolonged-release tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for upadacitinib (Rinvoq), prolonged-release tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, SL6 4UB - Maidenhead, United Kingdom.

EMA/PDCO/209075/2023 Corr[1]
Amsterdam, 21 July 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001741-PIP07-22

Scope of the application

Active substance(s):

Upadacitinib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of vitiligo

Pharmaceutical form(s):

Prolonged-release tablet

Age-appropriate oral dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted for agreement to the European Medicines Agency on 12 September 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 17 October 2022.

[1] 30 August 2023

Supplementary information was provided by the applicant on 24 March 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of vitiligo

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- prolonged-release tablet, age-appropriate oral dosage form; oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of vitiligo

2.1.1. Indication(s) targeted by the PIP

Treatment of nonsegmental vitiligo

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Prolonged-release tablet, age-appropriate oral dosage form.

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1** Development of an age-appropriate oral dosage form
Non-clinical studies	Not applicable
Clinical studies	**Study 2** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of upadacitinib in children from 12 years to less than 18 years of age (and adults) with nonsegmental vitiligo **Study 3** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of upadacitinib in children from 12 years to

	less than 18 years of age (and adults) with nonsegmental vitiligo **Study 4** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of upadacitinib in children from 6 years to less than 12 years of age with nonsegmental vitiligo
Modelling and simulation studies	**Study 5** Modelling and simulation study to evaluate the use of upadacitinib in children from 12 years to less than 18 years of age with nonsegmental vitiligo **Study 6** Modelling and simulation study to evaluate the use of upadacitinib in children from 6 years to less than 12 years of age with nonsegmental vitiligo
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By August 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of Rheumatoid arthritis

Authorised indication(s):

- Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.
  - Invented name(s): Rinvoq
  - Authorised pharmaceutical form(s): prolonged-release tablet
  - Authorised route(s) of administration: oral
  - Authorised via centralised procedure

2. Treatment of Psoriatic arthritis

- Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
  - Invented name(s): Rinvoq
  - Authorised pharmaceutical form(s): prolonged-release tablet
  - Authorised route(s) of administration: oral
  - Authorised via centralised procedure

3. Treatment of Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

- Rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

- Rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
  - Invented name(s): Rinvoq
  - Authorised pharmaceutical form(s): prolonged-release tablet
  - Authorised route(s) of administration: oral
  - Authorised via centralised procedure

4. Treatment of Atopic dermatitis

- Rinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

- Invented name(s): Rinvoq
- Authorised pharmaceutical form(s): prolonged-release tablet
- Authorised route(s) of administration: oral
- Authorised via centralised procedure

5. Treatment of Ulcerative Colitis

- Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
  - Invented name(s): Rinvoq
  - Authorised pharmaceutical form(s): prolonged-release tablet
  - Authorised route(s) of administration: oral
  - Authorised via centralised procedure

6. Treatment of Crohn's disease

- Rinvoq is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
  - Invented name(s): Rinvoq
  - Authorised pharmaceutical form(s): prolonged-release tablet
  - Authorised route(s) of administration: oral
  - Authorised via centralised procedure